May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Ability of Vitamin D Analogs to Induce Regression in Long Term Treatment of LHß-Tag Mice
Author Affiliations & Notes
  • S. Patel
    Ophthalmology, University of Wisconsin, Madison, WI, United States
  • D. Dawson
    Ophthalmology, University of Wisconsin, Madison, WI, United States
  • J. Gleiser
    Ophthalmology, University of Wisconsin, Madison, WI, United States
  • M. Zimbric
    Ophthalmology, University of Wisconsin, Madison, WI, United States
  • S. Darjatmoko
    Ophthalmology, University of Wisconsin, Madison, WI, United States
  • J. Lokken
    Ophthalmology, University of Wisconsin, Madison, WI, United States
  • M. Lindstrom
    Biostatistics, University of Wisconsin, Madison, WI, United States
  • J. Szpak
    Biostatistics, University of Wisconsin, Madison, WI, United States
  • D. Albert
    Biostatistics, University of Wisconsin, Madison, WI, United States
  • Footnotes
    Commercial Relationships  S. Patel, None; D. Dawson, None; J. Gleiser, None; M. Zimbric, None; S. Darjatmoko, None; J. Lokken, None; M. Lindstrom, None; J. Szpak, None; D. Albert, Bone Care International F.
  • Footnotes
    Support  NIH EYO 1917
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 1583. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      S. Patel, D. Dawson, J. Gleiser, M. Zimbric, S. Darjatmoko, J. Lokken, M. Lindstrom, J. Szpak, D. Albert; Ability of Vitamin D Analogs to Induce Regression in Long Term Treatment of LHß-Tag Mice . Invest. Ophthalmol. Vis. Sci. 2003;44(13):1583.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Two recently developed vitamin D analogues, 1α-hydroxyvitamin-D2 (1α-OH-D2) and 1,25-dihydroxy-16-ene-23-yne-vitamin D3 (16,23-D3) cause less toxicity than previously studied vitamin D compounds and have been shown to inhibit tumor growth in the athymic/Y-79 mouse model and a transgenic (LHß-Tag) model of the disease. It is not known whether with long-term treatment this tumor remains sensitive to these compounds or becomes refractory. This study examines the long-term ability of both vitamin D analogs to inhibit the growth of intraocular retinoblastoma in the transgenic mouse model. Methods: LHß-Tag transgenic 8-10 week old mice (N=120) were randomized to one of four treatment groups 0.5 µg/day of 16,23-D3 (IP injection; 40 mice/group), 0.2 µg/day of 1α-OH-D2 (oral gavage; 40 mice/group), mineral oil (IP injection control group; 20 mice/group), and coconut oil (control gavage group; 20 mice/group). One-third of the animals in each group were euthanized at 5, 10 and 15 weeks of treatment. At euthanization, the eyes were enucleated and blood was drawn for determination of serum calcium. The liver, lungs and kidneys were harvested. Three representative sections of each eye were stained with H&E, examined microscopically, and tumors were measured using Optimus software. Serum calcium level, kidney calcification, and liver and lung metastases were also examined. Results: At ten weeks the average tumor size of the 1α-OH-D2 treated group was 656,798 µm2 and was statistically different from the corresponding coconut oil control group 3,145,541 µm2 (p = 0.03). Average tumor size of the 16,23-D3 group (675,182 µm2) was not statistically different from the mineral oil control group (1,231,585 µm2) (p = 0.21). Conclusion: After ten weeks of vitamin D analogue therapy there was a statistically significant decrease in tumor size in the 1α-OH-D2 group when compared to the control group. At the same time point, 16,23-D3 was not significantly statistically different from its control group. 1α-OH-D2 shows similar effectiveness with long-term therapy as that previously published with 5-week therapy.

Keywords: retinoblastoma 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×